Summary of Action

Several class-action lawsuits have been filed across the country over the advertising of glucosamine supplements, all alleging that the various marketers of the products falsely label them as able to provide numerous joint benefits without having competent scientific evidence to support such marketing claims.

In the spring of 2017, the parties to a class action pending against the marketer of the TripleFlex line of glucosamine supplements reached a proposed settlement agreement that, among other things, would allow the company — Pharmavite — to continue its deceptive labeling (while prohibiting the nationwide class from ever doing anything about it) in exchange for paying a nominal sum to a small percentage of class members and more than $4 million to plaintiffs’ attorneys.

Because the agreement does not eradicate the deception at issue and is therefore unfair to consumers, filed a brief in November 2017 as amicus curiae opposing the proposed settlement. However, on December 4, 2017, the Court granted final approval of the settlement. Later that month, a class member who had objected to the fairness of the settlement filed a Notice of Appeal indicating he was appealing the Court’s final approval to the Ninth Circuit Court of Appeals but the appeal was later voluntarily dismissed.

For more information about’s position or to read the full brief, use the menu.

Print Friendly, PDF & Email

Tags: ,

Leave a Reply

Back to Top ↑